Search Results - "Melear J"

536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours.

Authors: Adjei, A.A. Beg, M. Melear, J. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS469-S469. 1p.

1437PPhase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Authors: Plummer, R Cook, N Arkenau, T et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Authors: Coombes RC Howell S Lord SR et al.

Source: Nature communications [Nat Commun] 2023 Aug 07; Vol. 14 (1), pp. 4741. Date of Electronic Publication: 2023 Aug 07.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Authors: Coombes RC Howell S Lord SR et al.

Source: Nature communications [Nat Commun] 2023 Jul 24; Vol. 14 (1), pp. 4444. Date of Electronic Publication: 2023 Jul 24.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Authors: Coombes RC Howell S Lord SR et al.

Source: Nature communications [Nat Commun] 2025 Mar 06; Vol. 16 (1), pp. 2242. Date of Electronic Publication: 2025 Mar 06.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.

Authors: Lee HJ Ramchandren R Friedman J et al.

Source: Blood [Blood] 2025 Jan 16; Vol. 145 (3), pp. 290-299.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

Authors: Yimer H Melear J Faber E et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2383-2392. Date of Electronic Publication: 2022 Jun 22.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA.

Authors: Sharman, J. Coleman, M. Yacoub, A. et al.

Source: Hematological oncology Jun2019 Supplement S2; Vol. 37.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232

MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA.

Authors: Sharman, J. Coleman, M. Yacoub, A. et al.

Source: Hematological oncology Jun2019 Supplement S2; Vol. 37.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.

Authors: Yimer H Melear J Faber E et al.

Source: British journal of haematology [Br J Haematol] 2019 May; Vol. 185 (3), pp. 492-502. Date of Electronic Publication: 2019 Mar 03.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Children's conceptions of death.

Authors: Melear JD

Source: The Journal of genetic psychology [J Genet Psychol] 1973 Dec; Vol. 123 (2d Half), pp. 359-60.

Publication Type: Journal Article

Journal Info: Publisher: Psychology Press Country of Publication: United States NLM ID: 2985112R Publication Model: Print Cited Medium: Print ISSN: 0022-1325 (Print) Linking ISSN: 00221325 NLM ISO Abbreviation: J Genet Psychol Subsets: MEDLINE